age, lower functional status (HAQ-S), presence of HLA-B27, and positive MRI of the SI joints were the strongest predictors of ASAS PR ( Figure) . (SpA) is considered a risk indicator for the presence of axial spondyloarthritis (axSpA) in patients with chronic back pain (CBP). In the ASAS classification criteria, a PFH of SpA is defined as the presence of any of the following diseases in firstor second-degree relatives: ankylosing spondylitis (AS), acute anterior uveitis (AAU), reactive arthritis (ReA), inflammatory bowel disease (IBD), and psoriasis. It is however not known if a PFH for each of these diseases contributes equally well to making a diagnosis of axSpA in patients presenting with CBP. Objectives: To assess which SpA diseases in family members are associated with HLA-B27 and axSpA in patients with CBP. Methods: The SPACE cohort includes patients with CBP (≥3 months, ≤2 years, onset <45 years) from various European rheumatology centers. DESIR is a French prospective multicenter cohort of patients with inflammatory back pain (IBP; ≥3 months, <3 years, onset <50 years), suggestive of axSpA. Patients underwent a full diagnostic work-up at baseline including MRI and radiographs of sacroiliac joints (local reading), laboratory assessments (e.g. HLA-B27), and assessment of all other SpA features. Patients were asked about the presence of SpA diseases in first-or second-degree relatives (AS, AAU, ReA, IBD, and psoriasis). The associations between a PFH and HLA-B27, sacroiliitis, axSpA diagnosis by the rheumatologist, and fulfilment of the ASAS classification criteria in CBP patients were assessed. Results: In 438 patients from the SPACE cohort and 647 patients from the DESIR cohort, a PFH of AS (odds ratio (OR) 5.9 (3.5-9.9) and OR 3.3 (2.1-5.2), respectively for SPACE and DESIR) and a PFH of AAU ) and OR 21.6 (2.9-160.1)) were significantly associated with presence of HLA-B27 (Table 1) .Furthermore, in both cohorts a PFH of AS and a PFH of AAU were positively associated with fulfilment of the ASAS-criteria, but not with sacroiliitis on imaging (data not shown). In SPACE, but not in DESIR, a PFH of AS or AAU was associated with axSpA diagnosis (data not shown). In both cohorts, a PFH of ReA, IBD, or psoriasis was not positively associated with HLA-B27 positivity, sacroiliitis on imaging, axSpA diagnosis or meeting the ASAS criteria for axSpA. Conclusions: In two recent CBP cohorts, a PFH of ReA, IBD, or psoriasis did not
